JP2011509071A - 炎症性腸疾患のための遺伝子発現マーカー - Google Patents

炎症性腸疾患のための遺伝子発現マーカー Download PDF

Info

Publication number
JP2011509071A
JP2011509071A JP2010536200A JP2010536200A JP2011509071A JP 2011509071 A JP2011509071 A JP 2011509071A JP 2010536200 A JP2010536200 A JP 2010536200A JP 2010536200 A JP2010536200 A JP 2010536200A JP 2011509071 A JP2011509071 A JP 2011509071A
Authority
JP
Japan
Prior art keywords
ibd
expression
seq
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010536200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509071A5 (enExample
Inventor
アレクサンダー， アール． アッバス，
ヒラリー クラーク，
ローリ ディール，
チャールズ リーズ，
コリン， エル． ノーブル，
ジャック サトサンギ，
Original Assignee
ジェネンテック， インコーポレイテッド
ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ オブ オールド カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/064562 external-priority patent/WO2008147900A2/en
Application filed by ジェネンテック， インコーポレイテッド, ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ オブ オールド カレッジ filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2011509071A publication Critical patent/JP2011509071A/ja
Publication of JP2011509071A5 publication Critical patent/JP2011509071A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010536200A 2007-11-29 2008-11-26 炎症性腸疾患のための遺伝子発現マーカー Pending JP2011509071A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99120307P 2007-11-29 2007-11-29
PCT/US2008/064562 WO2008147900A2 (en) 2007-05-22 2008-05-22 Gene expression markers for inflammatory bowel disease
US19226808P 2008-09-17 2008-09-17
PCT/US2008/085045 WO2009073565A2 (en) 2007-11-29 2008-11-26 Gene expression markers for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2011509071A true JP2011509071A (ja) 2011-03-24
JP2011509071A5 JP2011509071A5 (enExample) 2013-01-17

Family

ID=40459795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536200A Pending JP2011509071A (ja) 2007-11-29 2008-11-26 炎症性腸疾患のための遺伝子発現マーカー

Country Status (9)

Country Link
EP (1) EP2261367A3 (enExample)
JP (1) JP2011509071A (enExample)
KR (1) KR20110015409A (enExample)
CN (1) CN101970689A (enExample)
AU (1) AU2008334095A1 (enExample)
CA (1) CA2706729A1 (enExample)
IL (2) IL206014A (enExample)
MX (1) MX2010005893A (enExample)
WO (1) WO2009073565A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016217956A (ja) * 2015-05-25 2016-12-22 ヤマサ醤油株式会社 炎症性腸疾患のバイオマーカーとしてのｓ１００ａ９の使用
JP2019527039A (ja) * 2016-07-05 2019-09-26 ケンブリッジ エンタープライズ リミテッド 炎症性腸疾患用のバイオマーカー
JP2021185817A (ja) * 2020-05-29 2021-12-13 独立行政法人国立病院機構 バイオマーカー及びインターフェロンγ関連遺伝子のバイオマーカーとしての使用
JP2022545252A (ja) * 2019-08-23 2022-10-26 インシリコ メディシン アイピー リミテッド 特定の生物学的標的に対して生物学的活性を有する化合物を生成するためのワークフロー

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276392A1 (en) * 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
EP2486130A1 (en) * 2009-10-06 2012-08-15 Tallinn University Of Technology Inhibition or activation of serine/threonine ulk3 kinase activity
WO2011127351A1 (en) * 2010-04-09 2011-10-13 Exagen Diagnostics, Inc. Biomarkers for ulcerative colitis and crohn's disease
EP2576838A4 (en) * 2010-06-04 2019-05-15 Nestec S.A. METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN103336914B (zh) * 2013-05-31 2016-05-25 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
EP3736340A1 (en) * 2014-08-28 2020-11-11 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Methods and kit for identification of cancer
JP7082945B2 (ja) * 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CA3056911A1 (en) * 2017-03-23 2018-09-27 Meharry Medical College Methods for diagnosing and treating inflammatory bowel disease
CA3067397A1 (en) * 2017-06-20 2018-12-27 Meharry Medical College Targeted defa5 antibody and assay methods for diagnosing and treating inflammatory bowel disease
EP3774848B1 (en) * 2018-03-29 2023-02-22 Lateral Ip Pty Ltd Cyclic peptides and uses thereof
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN108893488A (zh) * 2018-06-19 2018-11-27 刘志强 一种重组质粒、dna疫苗及其制备方法和应用
WO2020000436A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种特异靶向人INDO基因的gRNA导向序列及其应用
EP3821246A4 (en) * 2018-07-15 2022-06-22 Rambam Med-Tech Ltd. Determining responders to inflammation treatment
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
WO2025029562A1 (en) * 2023-07-28 2025-02-06 The Johns Hopkins University Dna vaccines for eliciting t cell immunity in the lung
CN119236059B (zh) * 2024-10-11 2025-04-18 广东医科大学附属医院 Pdlim4基因在制备抑制非小细胞肺癌增殖的药物中的应用
CN119798401B (zh) * 2024-12-30 2025-10-10 常州因普迈生物科技有限公司 基于pdzk1ip1蛋白的多肽、抗体及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10327878A (ja) * 1997-03-14 1998-12-15 Smithkline Beecham Corp 腫瘍壊死因子関連のレセプター、ｔｒ６
JP2003512020A (ja) * 1999-03-04 2003-04-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DK0527283T3 (da) 1991-08-12 1998-08-10 Nestle Sa Levnedsmiddelsammensætning
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2223198A1 (en) 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
EP1287162A2 (en) * 1999-10-21 2003-03-05 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1844158A4 (en) * 2004-12-06 2010-09-08 Univ Johns Hopkins BIOMARKER FOR INFLAMMATORY ENDURANCE
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
AU2009215441B2 (en) * 2008-02-19 2015-07-02 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10327878A (ja) * 1997-03-14 1998-12-15 Smithkline Beecham Corp 腫瘍壊死因子関連のレセプター、ｔｒ６
JP2003512020A (ja) * 1999-03-04 2003-04-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5011008938; ＲＯＢＥＲＴ　ＢＥＲＫＯＷ: 'ＭＥＲＣＫ　ＭＡＮＵＡＬ　ＯＦ　ＤＩＡＧＮＯＳＩＳ　ＡＮＤ　ＴＨＥＲＡＰＹ，ＣＨＲＯＮＩＣ　ＩＮＦＬＡＭＭＡＴＯＲＹ　ＤＩＳＥＡＳＥＳ　ＯＦ　ＴＨＥ　ＢＯＷＥＬ' ＭＥＲＣＫ　ＭＡＮＵＡＬ　ＯＦ　ＤＩＡＧＮＯＳＩＳ　ＡＮＤ　ＴＨＥＲＡＰＹ , 19920101, Ｐ８３０-８３４, ＭＥＲＣＫ　ＲＥＳＥＡＲＣＨ　ＬＡＢＯＲＡＴＯＲＩＥＳ *
JPN6013037727; Ｆａｙａｄ　Ｒ．　ｅｔ　ａｌ: 'Ａｐｏｐｔｏｓｉｓ　ｒｅｓｉｓｔａｎｃｅ　ｉｎ　ｕｌｃｅｒａｔｉｖｅ　ｃｏｌｉｔｉｓ：　Ｈｉｇｈ　ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｄｅｃｏｙ　ｒｅｃｅｐｔｏｒｓ　ｂｙ　ｌａｍｉｎａ　ｐｒｏｐｒｉａ　Ｔ　ｃ' Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ ｖｏｌ．３６，　ｎｏ．８, 200608, ｐａｇｅｓ　２２１５-２２２２ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016217956A (ja) * 2015-05-25 2016-12-22 ヤマサ醤油株式会社 炎症性腸疾患のバイオマーカーとしてのｓ１００ａ９の使用
JP2019527039A (ja) * 2016-07-05 2019-09-26 ケンブリッジ エンタープライズ リミテッド 炎症性腸疾患用のバイオマーカー
JP2020198884A (ja) * 2016-07-05 2020-12-17 ケンブリッジ エンタープライズ リミテッド 炎症性腸疾患用のバイオマーカー
JP7111630B2 (ja) 2016-07-05 2022-08-02 ケンブリッジ エンタープライズ リミテッド 炎症性腸疾患用のバイオマーカー
JP2022545252A (ja) * 2019-08-23 2022-10-26 インシリコ メディシン アイピー リミテッド 特定の生物学的標的に対して生物学的活性を有する化合物を生成するためのワークフロー
JP7382489B2 (ja) 2019-08-23 2023-11-16 インシリコ メディシン アイピー リミテッド 特定の生物学的標的に対して生物学的活性を有する化合物を生成するためのワークフロー
US12293809B2 (en) 2019-08-23 2025-05-06 Insilico Medicine Ip Limited Workflow for generating compounds with biological activity against a specific biological target
JP2021185817A (ja) * 2020-05-29 2021-12-13 独立行政法人国立病院機構 バイオマーカー及びインターフェロンγ関連遺伝子のバイオマーカーとしての使用

Also Published As

Publication number Publication date
CN101970689A (zh) 2011-02-09
AU2008334095A1 (en) 2009-06-11
AU2008334095A2 (en) 2010-07-15
MX2010005893A (es) 2011-03-04
KR20110015409A (ko) 2011-02-15
EP2261367A2 (en) 2010-12-15
EP2261367A3 (en) 2011-03-23
IL206014A (en) 2014-07-31
IL233432A0 (en) 2014-08-31
IL206014A0 (en) 2010-11-30
WO2009073565A2 (en) 2009-06-11
WO2009073565A3 (en) 2009-09-24
CA2706729A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
JP2011509071A (ja) 炎症性腸疾患のための遺伝子発現マーカー
US20110033486A1 (en) Gene expression markers for crohn's disease
US20140179620A1 (en) Gene expression markers for inflammatory bowel disease
US20090186034A1 (en) Gene expression markers for inflammatory bowel disease
CA2726691C (en) Use of oncogene nrf2 for cancer prognosis
JP2009507229A (ja) 生物学的状態の診断及び／又は治療に有用なバイオマーカーを同定するための方法及び組成物
WO2014074942A1 (en) Risk variants of alzheimer's disease
JP2015519311A (ja) Ｉｌ−１７アンタゴニストを用いて強直性脊椎炎を治療する方法
US20250101517A1 (en) Identification of unique blood-based gene expression profiles in children with regressive autism spectrum disorder (asd) and ileocolitis
BR112016020987B1 (pt) Método de identificação de receptores de aloenxerto renal e método de seleção de receptor do aloenxerto renal
US20140037618A1 (en) Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2008147900A2 (en) Gene expression markers for inflammatory bowel disease
US20220290246A1 (en) Single nucleotide polymorphisms and uses thereof
US20100167285A1 (en) Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
JP2008539728A (ja) 膀胱癌バイオマーカーおよびその使用
WO2008079406A2 (en) Gene expression markers for inflammatory bowel disease
US20240301499A1 (en) Method for identifying hard-to-treat osteosarcoma patients at diagnosis and improving their outcome by providing new therapy
US20180073075A1 (en) Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypes
HK1174067A (en) Gene expression markers for crohn's disease
KR20180125911A (ko) 차세대서열분석 스크리닝을 통해 발굴한 단일염기다형성에 의한 염증성 장질환의 예측 또는 진단에 관한 정보 제공 방법
HK1116662A (en) Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
KR20180125778A (ko) 차세대서열분석 스크리닝을 통해 발굴한 단일염기다형성에 의한 염증성 장질환의 예측 또는 진단에 관한 정보 제공 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303